{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:17:51Z","timestamp":1790720271430,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health Labor and Welfare of Japan"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210058"],"award-info":[{"award-number":["JP20fk0210058"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00535-021-01845-5","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T19:03:36Z","timestamp":1642705416000},"page":"120-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis"],"prefix":"10.1007","volume":"57","clinical-trial-number":[{"clinical-trial-number":"umin000036150","registry":"10.18810\/umin-japan"}],"author":[{"given":"Yuki","family":"Tahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hikita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mochida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Yoshiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Hiasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Akuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokatsu","family":"Miyaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-3457","authenticated-orcid":false,"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"1845_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"1845_CR2","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599\u2013607.","journal-title":"N Engl J Med"},{"key":"1845_CR3","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062\u20138.","journal-title":"Lancet Infect Dis"},{"key":"1845_CR4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/hep4.1206","volume":"2","author":"Y Tahata","year":"2018","unstructured":"Tahata Y, Sakamori R, Urabe A, et al. Liver fibrosis is associated with corrected QT prolongation during Ledipasvir\/Sofosbuvir treatment for patients with chronic hepatitis C. Hepatol Commun. 2018;2:884\u201392.","journal-title":"Hepatol Commun"},{"key":"1845_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/hepr.13362","volume":"49","author":"T Mashiba","year":"2019","unstructured":"Mashiba T, Joko K, Kurosaki M, et al. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): a nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res. 2019;49:1114\u201320.","journal-title":"Hepatol Res"},{"key":"1845_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/hepr.13328","volume":"49","author":"E Ogawa","year":"2019","unstructured":"Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study. Hepatol Res. 2019;49:617\u201326.","journal-title":"Hepatol Res"},{"key":"1845_CR7","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67:1204\u201312.","journal-title":"J Hepatol"},{"key":"1845_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","volume":"67","author":"H Nagata","year":"2017","unstructured":"Nagata H, Nakagawa M, Asahina Y, et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67:933\u20139.","journal-title":"J Hepatol"},{"key":"1845_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/hepr.13454","volume":"50","author":"Y Tahata","year":"2020","unstructured":"Tahata Y, Sakamori R, Urabe A, et al. Hepatocellular carcinoma occurrence does not differ between interferon-based and interferon-free treatment with liver histological assessment. Hepatol Res. 2020;50:313\u201320.","journal-title":"Hepatol Res"},{"key":"1845_CR10","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/hepr.13547","volume":"50","author":"Y Tahata","year":"2020","unstructured":"Tahata Y, Sakamori R, Urabe A, et al. Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatol Res. 2020;50:1118\u201327.","journal-title":"Hepatol Res"},{"key":"1845_CR11","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/hep.29811","volume":"68","author":"LI Backus","year":"2018","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology. 2018;68:827\u201338.","journal-title":"Hepatology"},{"key":"1845_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.030","author":"GN Ioannou","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017. https:\/\/doi.org\/10.1016\/j.jhep.2017.08.030.","journal-title":"J Hepatol"},{"key":"1845_CR13","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328.","journal-title":"N Engl J Med"},{"key":"1845_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00535-018-1503-x","volume":"54","author":"T Takehara","year":"2019","unstructured":"Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87\u201395.","journal-title":"J Gastroenterol"},{"issue":"67","key":"1845_CR15","first-page":"1477","volume":"2018","author":"Panel A-IHG. Hepatitis C Guidance","year":"2018","unstructured":"Panel A-IHG. Hepatitis C Guidance. Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;2018(67):1477\u201392.","journal-title":"Clin Infect Dis"},{"key":"1845_CR16","unstructured":"European Association for the Study of the Liver (2018) Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69: 461\u2013511"},{"key":"1845_CR17","unstructured":"Tanaka A (2020) Drafting Committee for Hepatitis Management Guidelines tJSoH. JSH Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update. Hepatol Res"},{"key":"1845_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","volume":"13","author":"I Gentile","year":"2019","unstructured":"Gentile I, Scotto R, Coppola C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13:66\u201374.","journal-title":"Hepatol Int"},{"key":"1845_CR19","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cgh.2016.07.001","volume":"14","author":"R Maan","year":"2016","unstructured":"Maan R, van Tilborg M, Deterding K, et al. Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C Virus infection and cirrhosis. Clin Gastroenterol Hepatol. 2016;14:1821\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1845_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00535-020-01733-4","volume":"56","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Hikita H, Mochida S, et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study. J Gastroenterol. 2021;56:67\u201377.","journal-title":"J Gastroenterol"},{"key":"1845_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/hepr.13576","volume":"51","author":"Y Takaoka","year":"2021","unstructured":"Takaoka Y, Miura K, Morimoto N, et al. Real-world efficacy and safety of 12-week sofosbuvir\/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res. 2021;51:51\u201361.","journal-title":"Hepatol Res"},{"key":"1845_CR22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1111\/hepr.13555","volume":"50","author":"K Ohya","year":"2020","unstructured":"Ohya K, Imamura M, Teraoka Y, et al. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res. 2020;50:1234\u201343.","journal-title":"Hepatol Res"},{"key":"1845_CR23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","volume":"73","author":"EC Verna","year":"2020","unstructured":"Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73:540\u20138.","journal-title":"J Hepatol"},{"key":"1845_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"1845_CR25","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"key":"1845_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/hepr.13411","volume":"49","author":"N Kokudo","year":"2019","unstructured":"Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109\u201313.","journal-title":"Hepatol Res"},{"key":"1845_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/hepr.13623","volume":"51","author":"K Maesaka","year":"2021","unstructured":"Maesaka K, Sakamori R, Yamada R, et al. Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment. Hepatol Res. 2021;51:517\u201327.","journal-title":"Hepatol Res"},{"key":"1845_CR28","doi-asserted-by":"crossref","unstructured":"Examination Committee of Criteria for 'Obesity Disease' in J (2002) Japan Society for the Study of O. New criteria for 'obesity disease' in Japan. Circ J 66: 987\u2013992","DOI":"10.1253\/circj.66.987"},{"key":"1845_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1159\/000470910","volume":"93","author":"F Ogata","year":"2017","unstructured":"Ogata F, Kobayashi M, Akuta N, et al. Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease. Oncology. 2017;93:92\u20138.","journal-title":"Oncology"},{"key":"1845_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01463-18","author":"N Akuta","year":"2019","unstructured":"Akuta N, Suzuki F, Sezaki H, et al. Complex association of virus- and host-related factors with hepatocellular carcinoma rate following hepatitis C virus clearance. J Clin Microbiol. 2019. https:\/\/doi.org\/10.1128\/JCM.01463-18.","journal-title":"J Clin Microbiol"},{"key":"1845_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16632","author":"Y Tahata","year":"2021","unstructured":"Tahata Y, Sakamori R, Yamada R, et al. Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. Aliment Pharmacol Ther. 2021. https:\/\/doi.org\/10.1111\/apt.16632.","journal-title":"Aliment Pharmacol Ther"},{"key":"1845_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1845_CR33","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","volume":"17","author":"E Degasperi","year":"2019","unstructured":"Degasperi E, D\u2019Ambrosio R, Iavarone M, et al. Factors associated with increased risk of De Novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol. 2019;17:1183\u201391.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1845_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","volume":"155","author":"V Calvaruso","year":"2018","unstructured":"Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155:411\u201321.","journal-title":"Gastroenterology"},{"key":"1845_CR35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","volume":"73","author":"S Lens","year":"2020","unstructured":"Lens S, Baiges A, Alvarado-Tapias E, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020;73:1415\u201324.","journal-title":"J Hepatol"},{"key":"1845_CR36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/hep.30885","volume":"71","author":"M Mandorfer","year":"2020","unstructured":"Mandorfer M, Kozbial K, Schwabl P, et al. Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy. Hepatology. 2020;71:1023\u201336.","journal-title":"Hepatology"},{"key":"1845_CR37","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0168-8278(99)80142-1","volume":"30","author":"AW Schneider","year":"1999","unstructured":"Schneider AW, Kalk JF, Klein CP. Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. J Hepatol. 1999;30:876\u201381.","journal-title":"J Hepatol"},{"key":"1845_CR38","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","volume":"74","author":"LAP Krassenburg","year":"2021","unstructured":"Krassenburg LAP, Maan R, Ramji A, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74:1053\u201363.","journal-title":"J Hepatol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01845-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-021-01845-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-021-01845-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T11:05:50Z","timestamp":1644491150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-021-01845-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1007\/s00535-021-01845-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"13 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Satoshi Mochida received research grants from Janssen Pharmaceutical K. K., EA Pharma Co, Ltd., MIC Medical Corp., AbbVie GK, EPS International Holdings Co., Ltd. and Gilead Sciences, Inc. and scholarship grants from Toray Industries Inc, AbbVie GK, ASKA Pharmaceutical Co., Ltd, Eisai Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd and EA Pharma Co., Ltd. and is on the speakers\u2019 bureau for MSD K. K, Gilead Sciences, Inc, Toray Industries Inc, AbbVie GK, Sumitomo Dainippon Pharma Co., Ltd, Eisai Co., Ltd, Otsuka Pharmaceutical Co., Ltd and ASKA Pharmaceutical., Ltd. Norifumi Kawada received research grants from Takeda Pharmaceutical Company Limited, Chugai Pharmaceutical Co., Ltd, AstraZeneca plc, MSD co., Ltd, Gilead Sciences, Inc, GlaxoSmithKline plc and Bristol Myers Squibb. and scholarship grants from AbbVie GK, Otsuka Pharmaceutical Co., Ltd and Eisai Co., Ltd. and is on the speakers\u2019 bureau for AbbVie GK, MSD Co., Ltd and Gilead Sciences, Inc. Masayuki Kurosaki is on the speakers\u2019 bureau for Gilead Sciences, Inc and AbbVie GK. Hitoshi Yoshiji received research grants from AbbVie GK, Otsuka Pharmaceutical Co., Ltd and Asuka Pharmaceutical Co., Ltd. and is on the speakers\u2019 bureau for Gilead Sciences, Inc, Otsuka Pharmaceutical Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Asuka Pharmaceutical Co., Ltd and AbbVie GK. Naoya Kato received scholarship grants from Gilead Sciences, Inc. and is on the speakers\u2019 bureau for Gilead Sciences, Inc. Yoshiyuki Ueno received scholarship grants from AbbVie GK, EA Pharma and Otsuka Pharmatheutical and is on the speakers\u2019 bureau for EA Pharma, AbbVie GK. and Otsuka Pharmaceutical. Hiroshi Yatsuhashi received research grants from AbbVie GK. Yoshito Itoh received research grants from MSD, Gilead Sciences Inc and Bristol-Myers Squibb Company and scholarship grants from Bristol-Myers Squibb Company, AbbVie GK and MSD and is on the speakers\u2019 bureau for AbbVie GK, Gilead Sciences, Inc. and MSD. Goki Suda received research grants from Gilead Sciences, Inc. Taro Takami belongs to a donation-funded department funded by SHIBUYA Corporation. Yasuhiro Asahina belongs to a donation-funded department funded by Gilead Sciences, Inc., AbbVie GK, Toray Industries Inc and Fujirebio Inc. Tatsuya Kanto is on the speakers\u2019 bureau for Gilead Sciences, Inc.and AbbVie GK. Norio Akuta is on the speakers\u2019 bureau for AbbVie GK, Gilead Sciences, Inc. and Mitsubishi Tanabe Pharma Corporation. Shuji Terai received research grants from Intersterm Routo, Asuka, Tsumura, Abbot, Toso, Sysmex, Kowa, Stemrim, Towa, Gilead, Chiome, Shionogi, Niohonseiyaku, Kyowa and BioMimetics Sympathies and scholarship grants from AbbVie, Dainipponsumitomo, Aasakikasei, Niohokkayaku, Eisai, EA pharma, Boston and Takeda and is on the speakers\u2019 bureau for Otsuka, Gilead, Takeda, Asuka, MSD and DaiichiSankyo. Tetsuo Takehara received research grants from Gilead Sciences, Inc., MSD, AbbVie GK. and Chugai Pharmaceutical Co., Ltd. and is on the speakers\u2019 bureau for Gilead Sciences, Inc., AbbVie GK and MSD. All other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}